Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
MLYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.58 - $16.91
Previous CloseN/A
Volume137.34K
Average Volume (3M)299.92K
Market Cap
$474.93M
Enterprise Value$339.66M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.06
Next Earnings
May 19, 2025EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding49,835,636
10 Day Avg. Volume344,126
30 Day Avg. Volume299,923
Standard Deviation0.17
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.77
Forecast
1Y Price Target
$29.40Price Target Upside208.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Mineralys Therapeutics, Inc. News
PremiumCompany Announcements
Mineralys Therapeutics Highlights Positive Earnings Call
PremiumCompany Announcements
Mineralys Therapeutics Reports 2024 Earnings and Trial Progress
PremiumPre-Earnings
Is MLYS a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Clinical Trials And ResearchLorundrostat has demonstrated meaningful 8-10mm Hg blood pressure reduction in patients on antihypertensive therapies, with enhanced response in obese patients and an overall well-tolerated profile.
Financial StabilityMineralys reported finishing the period with $263.6M in cash, cash equivalents, and investments, which is expected to fund operations into 2026.
Market OpportunityThe demographic for lorundrostat’s potential reach includes approximately 30-50% of adults with hypertension and 70-80% of adults with resistant hypertension due to its application in obstructive sleep apnea.
Bears Say
Clinical Trial RisksHyperkalemia is a key focus with the ASI mechanism, and the inclusion of lower eGFR could theoretically raise hyperkalemia rates.
Financial ConcernsYears of cash left is 1.1, indicating the company may need additional funding if operations continue at the current pace.
Funding NeedsMineralys reported FY 2024 earnings, finishing the period with $198.2M in cash, cash equivalents, and investments, which is expected to fund operations through Q1 2026.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $8.58 and its highest was $16.91 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $474.93M.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is May 19, 2025 which is in 86 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Feb 12, 2025. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.077 by $0.097.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -1.08.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 49,835,636 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.077. Following the earnings report the stock price went up 10.041%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
---
Mineralys Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.40 (208.50% Upside)
$29.40 (208.50% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.71%
12-Months-Change
Fundamentals
Return on Equity
-82.24%
Trailing 12-Months
Asset Growth
-18.17%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
---
MLYS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook overall with strong clinical progress and a solid financial position, despite increased R&D expenses and net loss. The company remains optimistic about upcoming data readouts and market potential for lorundrostat.Read More>---
MLYS Stock 12 Month Forecast
Average Price Target
$29.40
▲(208.50% Upside)
Technical Analysis
Ardelyx
―
Amphastar Pharmaceuticals
―
Rocket Pharmaceuticals
―
Kiniksa Pharmaceuticals
―
Kezar Life Sciences
―
Best Analysts Covering MLYS
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-12.75%
reiterated a buy rating 10 days ago
Copying Richard Law CFA's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -12.75% per trade.
---